Sign up to save your podcasts
Or
Share Interview with Neuromod COO Diarmuid Flavin About the FDA Approval of Tinnitus Treatment Lenire
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Interview with Neuromod COO Diarmuid Flavin About the FDA Approval of Tinnitus Treatment Lenire
This episode features an interview with Diarmuid Flavin, Chief Operating Officer (COO) of Neuromod, a Dublin-based medical device company specializing in the treatment of tinnitus, a condition known as “ringing in the ears.” Tinnitus is believed to impact between 10 to 15 percent of adults worldwide.
The company recently received De Novo approval from the FDA for its tinnitus treatment Lenire. Lenire is the first of its kind, non-invasive, bimodal neuromodulation device that stimulates nerves to treat tinnitus. Diarmuid spoke about the approval and how Lenire helps address a significant unmet need in the tinnitus space.
Diarmuid brings more than 25 years of global leadership experience in a range of medical device, technology, and pharmaceutical companies to Neuromod, where he assumes responsibility for the company’s strategic operational execution, Regulatory Affairs, Engineering & Technology, Manufacturing Operations and Supply Chain teams.
Hear more about Lenire and Neuromod’s continuing work in biomodal neuromodulation technologies.
Read more here:
Lenire Bimodal Neuromodulation Device by Neuromod Improves Tinnitus Symptoms in Clinical Trial
For more life science and medical device content, visit the Xtalks Vitals homepage.
Follow Us on Social Media
Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
View all episodes
By XtalksThis episode features an interview with Diarmuid Flavin, Chief Operating Officer (COO) of Neuromod, a Dublin-based medical device company specializing in the treatment of tinnitus, a condition known as “ringing in the ears.” Tinnitus is believed to impact between 10 to 15 percent of adults worldwide.
The company recently received De Novo approval from the FDA for its tinnitus treatment Lenire. Lenire is the first of its kind, non-invasive, bimodal neuromodulation device that stimulates nerves to treat tinnitus. Diarmuid spoke about the approval and how Lenire helps address a significant unmet need in the tinnitus space.
Diarmuid brings more than 25 years of global leadership experience in a range of medical device, technology, and pharmaceutical companies to Neuromod, where he assumes responsibility for the company’s strategic operational execution, Regulatory Affairs, Engineering & Technology, Manufacturing Operations and Supply Chain teams.
Hear more about Lenire and Neuromod’s continuing work in biomodal neuromodulation technologies.
Read more here:
Lenire Bimodal Neuromodulation Device by Neuromod Improves Tinnitus Symptoms in Clinical Trial
For more life science and medical device content, visit the Xtalks Vitals homepage.
Follow Us on Social Media
Twitter: @Xtalks
Instagram: @Xtalks
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
More shows like Xtalks Life Science Podcast
View all
The Daily
111,437 Listeners
Crime Junkie
364,664 Listeners
Business Of Biotech
84 Listeners
BioCentury This Week
31 Listeners
Biotech Hangout
9 Listeners
HBR On Leadership
138 Listeners
The BioCentury Show
11 Listeners